Expert opinion on tilarginine in the treatment of shock

Author： Howes Laurence Guy   Brillante Divina Gracila  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.10, 2008-10, pp. : 1573-1580

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An expert opinion on the current treatment of anemia in patients with kidney disease

By Locatelli Francesco   Vecchio Lucia Del  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 495-503

Informa Healthcare

Access to resources Recommend Favorite

Treating arrhythmias: an expert opinion

By Dagres Nikolaos   Sommer Philipp   Anastasiou-Nana Maria   Hindricks Gerhard  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 9, 2011-06 ,pp. : 1359-1367

Informa Healthcare

Access to resources Recommend Favorite

Expert opinion in pharmacoeconomics

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 272, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Related articles in Expert Opinion

By  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 10, 2010-10 ,pp. : 1419-1420

Informa Healthcare

Access to resources Recommend Favorite

Tilarginine does not reduce the risk of mortality for patients with acute myocardial infarction (MI) and cardiogenic shock

By  

Inpharma, Vol. 1, Iss. 1581, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite